» Articles » PMID: 29795461

Epigallocatechin Gallate Targets FTO and Inhibits Adipogenesis in an MRNA MA-YTHDF2-dependent Manner

Overview
Specialty Endocrinology
Date 2018 May 26
PMID 29795461
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background/objective: N-methyladenosine (mA) modification of mRNA plays a role in regulating adipogenesis. However, its underlying mechanism remains largely unknown. Epigallocatechin gallate (EGCG), the most abundant catechin in green tea, plays a critical role in anti-obesity and anti-adipogenesis.

Methods: High-performance liquid chromatography coupled with triple-quadrupole tandem mass spectrometry (HPLC-QqQ-MS/MS) was performed to determine the mA levels in 3T3-L1 preadipocytes. The effects of EGCG on the mA levels in specific genes were determined by methylated RNA immunoprecipitation coupled with quantitative real-time PCR (meRIP-qPCR). Several adipogenesis makers and cell cycle genes were analyzed by quantitative real-time PCR (qPCR) and western blotting. Lipid accumulation was evaluated by oil red O staining. All measurements were performed at least for three times.

Results: Here we showed that EGCG inhibited adipogenesis by blocking the mitotic clonal expansion (MCE) at the early stage of adipocyte differentiation. Exposing 3T3-L1 cells to EGCG reduced the expression of fat mass and obesity-associated (FTO) protein, an mA demethylase, which led to increased overall levels of RNA mA methylation. Cyclin A2 (CCNA2) and cyclin dependent kinase 2 (CDK2) play vital roles in MCE. The mA levels of CCNA2 and CDK2 mRNA were dramatically enhanced by EGCG. Interestingly, EGCG increased the expression of YTH N-methyladenosine RNA binding protein 2 (YTHDF2), which recognized and decayed methylated mRNAs, resulting in decreased protein levels of CCNA2 and CDK2. As a result, MCE was blocked and adipogenesis was inhibited. FTO overexpression and YTHDF2 knockdown in 3T3-L1 cells significantly increased CCNA2 and CDK2 protein levels and ameliorated the EGCG-induced adipogenesis inhibition. Thus, mA-dependent CCNA2 and CDK2 expressions mediated by FTO and YTHDF2 contributed to EGCG-induced adipogenesis inhibition.

Conclusion: Our findings provide mechanistic insights into how mA is involved in the EGCG regulation of adipogenesis and shed light on its anti-obesity effect.

Citing Articles

Epigenetic Mechanisms in Osteoporosis: Exploring the Power of mA RNA Modification.

Tian S, Song Y, Guo L, Zhao H, Bai M, Miao M J Cell Mol Med. 2025; 29(1):e70344.

PMID: 39779466 PMC: 11710941. DOI: 10.1111/jcmm.70344.


N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications.

Wang Y, Zou J, Zhou H Front Endocrinol (Lausanne). 2024; 15:1462146.

PMID: 39296713 PMC: 11408340. DOI: 10.3389/fendo.2024.1462146.


The mA regulators in prostate cancer: molecular basis and clinical perspective.

Cao Y, Jia M, Duan C, Yang Z, Cheng B, Wang R Front Pharmacol. 2024; 15:1448872.

PMID: 39268470 PMC: 11391310. DOI: 10.3389/fphar.2024.1448872.


A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis.

Chavez-Lopez L, Carballo-Lopez G, Lugo-Ibarra K, Castro-Cesena A RSC Med Chem. 2024; 15(8):2622-2642.

PMID: 39149095 PMC: 11324041. DOI: 10.1039/d4md00420e.


The YTH domain-containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.

Li F, Zeng C, Liu J, Wang L, Yuan X, Yuan L Clin Transl Med. 2024; 14(8):e1784.

PMID: 39135292 PMC: 11319238. DOI: 10.1002/ctm2.1784.